
Sino Biopharmaceutical Limited
1177.HKHKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$5.59
−HK$0.015 · -0.27%
1177.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteSino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- HK
- CEO
- S Y Tse
- Listed since
- May 12, 2004
- Employees
- 22,838
Market position
- Volume
- 94.31M
- 1.03× average
- Average volume
- 91.76M
- Average daily volume
- Market cap
- 99.4B HKD
- Beta
- 0.62
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 108.9B CNY
- EV / EBITDA
- 15.01×
- Earnings yield
- 2.34%
- Free cash flow yield
- 7.57%
Profitability & efficiency
- Return on equity
- 7.64%
- Return on assets
- 3.08%
- Return on invested capital
- 8.98%
Financial health
- Current ratio
- 1.37×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 31.83B CNY | 28.87B CNY | 26.2B CNY | 26.03B CNY | 26.86B CNY |
| Cost of goods sold | 5.71B CNY | 5.34B CNY | 4.99B CNY | 5.8B CNY | 5.33B CNY |
| Gross profit | 26.13B CNY | 23.53B CNY | 21.21B CNY | 21.54B CNY | 21.53B CNY |
| Research and development | 6.04B CNY | 5.23B CNY | 4.47B CNY | 4.33B CNY | 3.75B CNY |
| Selling, general, and administrative | 13.14B CNY | 12.16B CNY | 11.07B CNY | 12.56B CNY | 12.7B CNY |
| Operating expenses | 19.17B CNY | 17.39B CNY | 15.54B CNY | 15.95B CNY | 17.19B CNY |
| Interest income | 617.19M CNY | 499.56M CNY | 186.68M CNY | 195.91M CNY | 162.06M CNY |
| Interest expense | 271.11M CNY | 295.12M CNY | 495.24M CNY | 429.49M CNY | 308.62M CNY |
| Depreciation and amortization | 963.9M CNY | 939.85M CNY | 1.07B CNY | 1.05B CNY | 992.56M CNY |
| Operating income | 6.95B CNY | 6.14B CNY | 5.79B CNY | 5.59B CNY | 5.08B CNY |
| Net income | 2.34B CNY | 3.5B CNY | 2.33B CNY | 2.54B CNY | 14.61B CNY |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- +8.01%
- 11 comparable reports
- Latest EPS result
- 0.22
- Estimate 0.14 · Beat by 58.56%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 24, 2026 | HK$0.07Semi-Annual | Sep 3, 2026 | Sep 24, 2026 |
Dividend | Aug 29, 2025 | HK$0.05Semi-Annual | Sep 1, 2025 | Sep 23, 2025 |
Dividend | Jun 16, 2025 | HK$0.04Semi-Annual | Jun 17, 2025 | Jul 10, 2025 |
Dividend | Sep 10, 2024 | HK$0.03Semi-Annual | Sep 11, 2024 | Oct 4, 2024 |
Dividend | Jun 11, 2024 | HK$0.03Semi-Annual | Jun 12, 2024 | Jul 5, 2024 |
Dividend | Oct 4, 2023 | HK$0.02Semi-Annual | Oct 5, 2023 | Oct 27, 2023 |
Ex-dividend Jun 24, 2026
HK$0.07
Semi-Annual
Record Sep 3, 2026 · Payment Sep 24, 2026
Ex-dividend Aug 29, 2025
HK$0.05
Semi-Annual
Record Sep 1, 2025 · Payment Sep 23, 2025
Ex-dividend Jun 16, 2025
HK$0.04
Semi-Annual
Record Jun 17, 2025 · Payment Jul 10, 2025
Ex-dividend Sep 10, 2024
HK$0.03
Semi-Annual
Record Sep 11, 2024 · Payment Oct 4, 2024
Ex-dividend Jun 11, 2024
HK$0.03
Semi-Annual
Record Jun 12, 2024 · Payment Jul 5, 2024
Ex-dividend Oct 4, 2023
HK$0.02
Semi-Annual
Record Oct 5, 2023 · Payment Oct 27, 2023
1177.HK peers
ETFs holding 1177.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS90.37M0.01%646.2B USD0.05%$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO87.3M0.05%162.3B USD0.06%$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG76.93M0.05%160B USD0.09%$81.57+0.64%
Global X China Biotech ETF (HKD)2820.HK24.71M4.06%701.08M HKD0.68%HK$73.30-4.18%
Avantis Emerging Markets Equity ETFAVEM24.6M0.09%27.89B USD0.33%$94.24+0.75%
JPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETFBBAX20.2M0.29%6.92B USD0.19%$65.27+1.18%
iShares MSCI Emerging Markets ETFEEM17.37M0.06%31.22B USD0.72%$67.12+0.75%
iShares MSCI China ETFMCHI16.55M0.26%6.29B USD0.59%$55.66+0.27%
Vanguard Total International Stock ETFVXUS- Market value
- 90.37M
- Weight
- 0.01%
- AUM
- 646.2B USD
- Expense ratio
- 0.05%
- Price / 1D
- $87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO- Market value
- 87.3M
- Weight
- 0.05%
- AUM
- 162.3B USD
- Expense ratio
- 0.06%
- Price / 1D
- $60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG- Market value
- 76.93M
- Weight
- 0.05%
- AUM
- 160B USD
- Expense ratio
- 0.09%
- Price / 1D
- $81.57+0.64%
Global X China Biotech ETF (HKD)2820.HK- Market value
- 24.71M
- Weight
- 4.06%
- AUM
- 701.08M HKD
- Expense ratio
- 0.68%
- Price / 1D
- HK$73.30-4.18%
Avantis Emerging Markets Equity ETFAVEM- Market value
- 24.6M
- Weight
- 0.09%
- AUM
- 27.89B USD
- Expense ratio
- 0.33%
- Price / 1D
- $94.24+0.75%
JPMorgan BetaBuilders Developed Asia Pacific ex-Japan ETFBBAX- Market value
- 20.2M
- Weight
- 0.29%
- AUM
- 6.92B USD
- Expense ratio
- 0.19%
- Price / 1D
- $65.27+1.18%
iShares MSCI Emerging Markets ETFEEM- Market value
- 17.37M
- Weight
- 0.06%
- AUM
- 31.22B USD
- Expense ratio
- 0.72%
- Price / 1D
- $67.12+0.75%
iShares MSCI China ETFMCHI- Market value
- 16.55M
- Weight
- 0.26%
- AUM
- 6.29B USD
- Expense ratio
- 0.59%
- Price / 1D
- $55.66+0.27%
Continue in GoAI
Research 1177.HKresearch.disclaimer





